Funda Meric‐Bernstam

Zanidatamab in patients with early stage HER2-positive breast cancer: the NeoZanHER phase 2 single-arm open-label trial

Strategies are needed to avoid chemotherapy in early stage HER2-positive (HER2 + ) breast cancer (BC). We conducted a neoadjuvant therapy trial with zanidatamab, a dual HER2-directed bispecific antibody, in patients with 1-3 cm, node-negative HER2 + BC. Primary endpoint was patho...

Proteogenomic profiling identifies FGFR2b as a prevalent cell-surface target in intrahepatic cholangiocarcinoma

Abstract Purpose: Intrahepatic cholangiocarcinoma (iCCA) is rising in incidence and is associated with limited treatment options and poor prognosis, particularly in advanced disease. Recently, biologic strategies such as antibody–drug conjugates (ADCs) have expanded therapeutic o...